[1]谭亮,王菊,鲜继淑,等.134例凝血功能障碍所致脑出血的临床特点分析[J].第三军医大学学报,2019,41(07):701-705.
 TAN Liang,WANG Ju,XIAN Jishu,et al.Clinical features and outcomes of intracerebral hemorrhage induced by coagulation dysfunction: analysis of 134 cases [J].J Third Mil Med Univ,2019,41(07):701-705.
点击复制

134例凝血功能障碍所致脑出血的临床特点分析(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
41卷
期数:
2019年第07期
页码:
701-705
栏目:
临床医学
出版日期:
2019-04-15

文章信息/Info

Title:
Clinical features and outcomes of intracerebral hemorrhage induced by coagulation dysfunction: analysis of 134 cases
 
作者:
谭亮王菊鲜继淑蒋周阳缪洪平张超胡荣冯华  
陆军军医大学(第三军医大学)第一附属医院神经外科
 
Author(s):
TAN Liang WANG Ju XIAN Jishu JIANG Zhouyang MIAO Hongping ZHANG Chao HU Rong FENG Hua

Department of Neurosurgery, First Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400038, China

关键词:
凝血功能障碍脑出血手术治疗
Keywords:
coagulation dysfunction intracerebral hemorrhage surgery  
分类号:
R181.32; R554; R743.34
文献标志码:
A
摘要:

目的分析凝血功能障碍所导致脑出血的临床特点,探讨有效的治疗方法。方法收集2000年1月至2016年8月本科收治的凝血功能障碍所致脑出血患者134例,分析其凝血障碍类型、治疗方式、病死率、出院时改良兰金量表评分(modified rankin scale,mRS)、围手术期并发症(血肿扩大、肺部感染、脑积水、上消化道出血、深静脉血栓等)。结果出院时按mRS评分评估患者的预后,病死(mRS:6分)54例,严重残疾(mRS:3~5分)47例,预后良好(mRS:1~2分)33例;其中华法林和血液病所致脑出血的预后最差,病死率达50%以上。对于出血量为>30~80 mL的脑出血患者,32例(47%)采取保守治疗,其中23例患者死亡,病死率为71.9%;36例(53%)采取手术治疗,其中16例患者死亡,病死率为44.4%。手术组病死率显著低于保守治疗组(P<0.05)。手术组病例住院时间为(17.02±5.90)d,显著短于保守治疗组病例住院时间[(20.09±5.35)d,P<0.05]。结论凝血功能障碍所致脑出血患者预后较差,应严密监测各项凝血功能,并在早期迅速纠正凝血功能,预防并发症;早期手术治疗对于血肿较大的凝血功能障碍性脑出血患者预后有改善作用。

 

Abstract:

Objective To analyze the clinical characteristics and outcomes of intracerebral hemorrhage induced by coagulation dysfunction and explore its optimal interventions. Methods From January 2000 to August 2016, a total of 134 patients with cerebral hemorrhage caused by coagulation dysfunction were admitted in our department. The types of coagulation disorders, interventions, mortality, modified Rankin Scale (mRS) scores at discharge, and perioperative complications (hematoma enlargement, pulmonary infection, hydrocephalus, alimentary tract hemorrhage, and deep venous thrombosis) were analyzed in these patients. Results The prognosis of the patients was evaluated based on mRS scores at discharge. Among the 134 patients, 54 died (mRS score of 6), 47 had severe disabilities (mRS scores of 3~5), and 33 had favorable prognoses (mRS scores of 1~2). The patients with intracerebral hemorrhage associated with the use of warfalin and hematologic disease had the worst prognosis with a mortality rate above 50%. In the patients with a hemorrhage volume of >30~80 mL, 32 received conservative treatment and 36 underwent surgical interventions, and the mortality rate was significantly higher in the patients with conservative treatment  than those undergoing surgical treatment (71.9% vs 44.4%, P<0.05); the average length of hospital stay was also significantly longer in the conservative treatment group than in the surgical group (20.09±5.35 vs 17.02±5.90 d, P<0.05). Conclusion The patients with intracerebral hemorrhage caused by coagulation dysfunction have poorer outcomes than those with hypertensive intracerebral hemorrhage. Early and effective interventions of coagulation dysfunction, close monitoring of potential complications and early surgical intervention can improve the outcomes of patients with large intracerebral hematoma.
 

参考文献/References:

[1]KAWANOCASTILLO J, WARD E, ELLIOTT A, et al. Thrombelastography detects possible coagulation disturbance in patients with intracerebral hemorrhage with hematoma enlargement[J]. Stroke, 2014, 45(3): 683-688. DOI: 10.1161/STROKEAHA.113.003826.
[2]MA M M, MERETOJA A, CHURILOV L, et al. Warfarinassociated intracerebral hemorrhage: volume, anticoagulation intensity and location[J]. J Neurol Sci, 2013, 332(1/2): 75-79. DOI: 10.1016/j.jns.2013.06.020.
[3]ROSAND J, ECKMAN M H, KNUDSEN K A, et al. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage[J]. Arch Intern Med, 2004, 164(8): 880-884. DOI: 10.1001/archinte.164.8.880.
[4]SJ BLOM L, H RDEMARK H G, LINDGREN A, et al. Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: a Swedish multicenter study[J]. Stroke, 2001, 32(11): 2567-2574.
[5]MAYER S A, BRUN N C, BEGTRUP K, et al. Efficacy and safety of recombinant activated factor Ⅶ for acute intracerebral hemorrhage[J]. N Engl J Med, 2008, 358(20): 2127-2137. DOI: 10.1056/NEJMoa0707534.
[6]FLIBOTTE J J, HAGAN N, O’DONNELL J, et al. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage[J]. Neurology, 2004, 63(6): 1059-1064.
[7]鲁大双, 王启华, 崔杰, 等. 凝血功能障碍性脑出血的治疗[J]. 海南医学院学报, 2012, 18(1): 74-76. DOI: 461049/R.20111202.1034.007. 
LU D S,WANG Q H,CUI J, et al. Treatment for cerebral hemorrhage due to coagulation disorders [J]. J Hainan Med Univ, 2012, 18(1): 74-76. DOI: 461049/R.20111202.1034.007.
[8]ROMERO N, LUPI K, CARTER D, et al. The role of double and triple therapy with direct oral anticoagulants in coronary artery disease, peripheral artery disease, and stroke[J]. Clin Ther, 2018, 40(11): 1907-1917.e3. DOI:10.1016/j.clinthera.2018.09.014.
[9]YASAKA M. New insights into nonvitamin K antagonist oral anticoagulants’ reversal of intracerebral hemorrhage[J]. Front Neurol Neurosci, 2015, 37: 93-106. DOI: 10.1159/000437116.
[10]GREENBLATT D J, VON MOLTKE L L. Interaction of warfarin with drugs, natural substances, and foods[J]. J Clin Pharmacol, 2005, 45(2): 127-132. DOI: 10.1177/0091270004271404.
[11]KURAMATSU J B, GERNER S T, SCHELLINGER P D, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulationrelated intracerebral hemorrhage[J]. JAMA, 2015, 313(8): 824-836. DOI: 10.1001/jama.2015.0846.
[12]TAKARADA K, SATO M, GOTO M, et al. Longterm PT-INR levels and the clinical events in the patients with non-valvular atrial fibrillation: a special reference to lowintensity warfarin therapy[J]. J Cardiol, 2014, 64(2): 127-132. DOI: 10.1016/j.jjcc.2013.11.015.
[13]YU Y, WU J, ZHAO W, et al. Calibrated automated thrombography for monitoring coagulation function in patients with intracerebral haemorrhage[J]. J Int Med Res, 2015, 43(3): 316-325. DOI: 10.1177/0300060514565801.
[14]BURCHELL S R, TANG J P, ZHANG J H. Hematoma expansion following intracerebral hemorrhage: mechanisms targeting the coagulation cascade and platelet activation[J]. Curr Drug Targets, 2017, 18(12): 1329-1344. DOI: 10.2174/1389450118666170329152305.
[15]CORDONNIER C, DEMCHUK A, ZIAI W, et al. Intracerebral haemorrhage: current approaches to acute management[J]. Lancet, 2018, 392(10154): 1257-1268. DOI: 10.1016/s0140-6736(18)31878-6.
[16]BRAILOIU E, BARLOW C L, RAMIREZ S H, et al. Effects of platelet-activating factor on brain microvascular endothelial cells[J]. Neuroscience, 2018, 377: 105-113. DOI: 10.1016/j.neuroscience.2018.02.039.
 

相似文献/References:

[1]李志伟.微创血肿清除术治疗脑出血的诊治体会[J].第三军医大学学报,2007,29(21):2107.
[2]文华海.脑出血3例误诊分析[J].第三军医大学学报,2007,29(15):1522.
[3]崔洁,曹参祥,郑静,等.脑出血大鼠脑组织MDA、TNF-α含量变化及其依达拉奉干预效应的研究[J].第三军医大学学报,2007,29(11):1032.
 CUI Jie,CAO Can-xiang,ZHENG Jing,et al.Changes of TNF-alpha and malondialdehyde content in brain tissue and therapeutic effect of edaravone on rats after intracerebral hemorrhage[J].J Third Mil Med Univ,2007,29(07):1032.
[4]邹显巍,吴珊.大鼠脑出血后脑肺组织NF-κB的表达及其在急性肺损伤中的作用[J].第三军医大学学报,2007,29(19):1859.
 ZOU Xian-wei,WU Shan.Expression of NF-κB in the brain and lung and its role in acute lung injury following intracerebral hemorrhage of rats[J].J Third Mil Med Univ,2007,29(07):1859.
[5]袁建国,向强,熊建琼,等.急诊微创介入术对高血压脑出血的救治研究[J].第三军医大学学报,2006,28(19):1989.
[6]廖群纷,梁德胜,王为民,等.脑出血患者血清S100b蛋白与神经功能损害的相关性研究[J].第三军医大学学报,2005,27(14):1494.
[7]王苇,张新江,殷小平,等.脑出血超早期血肿周围病变的MRI研究及其临床意义[J].第三军医大学学报,2005,27(05):422.
[8]周宇燕.高血压脑出血颅内血肿微创清除术后再出血的观察与护理[J].第三军医大学学报,2005,27(04):290.
[9]汤可,周青,周敬安,等.脑出血破入脑室的高龄重症患者死亡危险因素分析[J].第三军医大学学报,2011,33(16):1773.
[10]何程,林爱国,王俊伟,等.术中B超辅助下经外侧裂-岛叶入路显微手术治疗基底节区脑出血[J].第三军医大学学报,2010,32(13):1468.

更新日期/Last Update: 2019-04-05